Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) research hub

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

This study looks at how a medicine called apalutamide works for men with prostate cancer that has spread. It checks if the medicine helps, how it affects daily life, and gathers real-world information beyond strict trials.

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

This study looks at new combinations of medicines for men with prostate cancer that has spread. It checks if combining a new drug, tulmimetostat, with existing treatments like darolutamide or abiraterone is safe and works well. The goal is to find better ways to treat this type of cancer.

(21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).